I rarely ever stop to read their replicated press releases—read the press release and read the article. They're basically the same thing. ScienceDaily just regurgitates source articles; any grievance one has with the article should instead be taken with the issuing University. It's why there's such high variance in the quality of ScienceDaily articles.
They provide a link here: http://www.eurekalert.org/pub_releases/2015-05/uoc--dpu05121...
And provide a title: Journal Reference:
David Schaffer et al. Systemic attenuation of the TGF-β pathway by a single drug simultaneously rejuvenates hippocampal neurogenesis and myogenesis in the same old mammal. Oncotarget, May 201
I find that an incredibly useful service since,often, even press releases can't be bothered to link to or at least, write the name of the paper under discussion.http://www.impactjournals.com/oncotarget/index.php?journal=o...
The pdf: http://www.impactjournals.com/oncotarget/index.php?journal=o...
That process can and should be drastically improved, though.
We should also look at the article under consideration. It seems to describe a molecule that might "cure" or ameliorate the effects of aging. Extraordinary claims need extraordinary evidence but even more, there's a big "push" to have something like this published given that in there would be a tremendous amount of money interested in investing in a project that appears to have even a one percent chance of being that big.